Oncotarget

Research Papers:

The serine protease matriptase inhibits migration and proliferation in multiple myeloma cells

Ida Steiro _, Esten N. Vandsemb, Samah Elsaadi, Kristine Misund, Anne-Marit Sponaas, Magne Børset, Pegah Abdollahi and Tobias S. Slørdahl

PDF  |  Full Text  |  Supplementary Files  |  How to cite  |  Press Release  |  Order a Reprint

Oncotarget. 2022; 13:1175-1186. https://doi.org/10.18632/oncotarget.28300

Metrics: PDF 157 views  |   Full Text 947 views  |   ?  


Abstract

Ida Steiro1, Esten N. Vandsemb1, Samah Elsaadi1, Kristine Misund1, Anne-Marit Sponaas1, Magne Børset1,2, Pegah Abdollahi1,3 and Tobias S. Slørdahl1,4

1 Center for Myeloma Research, Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway

2 Department of Immunology and Transfusion Medicine, St. Olav's University Hospital, Trondheim, Norway

3 Laboratory Clinic, St. Olav's University Hospital, Trondheim, Norway

4 Department of Hematology, St. Olav's University Hospital, Trondheim, Norway

Correspondence to:

Ida Steiro, email: ida.j.steiro@ntnu.no

Keywords: matriptase; multiple myeloma; tumor suppressor; migration; Src

Received: September 08, 2022     Accepted: October 12, 2022     Published: October 20, 2022

Copyright: © 2022 Steiro et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

Background: Multiple myeloma (MM) is an incurable malignancy of plasma cells. The serine protease matriptase is frequently dysregulated in human carcinomas, which facilitates tumor progression and metastatic dissemination. The importance of matriptase in hematological malignancies is yet to be clarified. In this study, we aimed to characterize the role of matriptase in MM.

Materials and Methods: mRNA expression of matriptase and its inhibitors hepatocyte growth factor activator inhibitor (HAI)-1 and HAI-2 was studied in primary MM cells from patient samples and human myeloma cell lines (HMCLs). We further investigated the effect of matriptase on migration and proliferation of myeloma cells in vitro. By use of the CoMMpass database, we assessed the clinical relevance of matriptase in MM patients.

Results: Matriptase was expressed in 96% of patient samples and all HMCLs tested. Overexpression of matriptase in vitro reduced proliferation, and significantly decreased cytokine-induced migration. Conversely, matriptase knockdown significantly enhanced migration. Mechanistically, overexpression of matriptase inhibited activation of Src kinase.

Conclusions: Our findings may suggest a novel role of matriptase as a tumor suppressor in MM pathogenesis.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 28300